BioTheryX names new director
12 November 2019 -

BioTheryX Incorporated, a clinical stage biotechnology company creating new classes of drugs for unmet medical needs based on targeted protein degradation and multi-kinase inhibition, announced yesterday that it has named Peter N Crnkovich as its new director.

Since September 2018, Crnkovich has served as a senior consultant at the company. Presently, he serves as a senior advisor at Morgan Stanley, prior to his retirement from Morgan Stanley after 34 years, he held a variety of positions there, including most recently as chairman of the Global Health Care Group. He is also a senior advisor at Riboscience LLC.

David Stirling, CEO and founder of BioTheryX, said, 'We are delighted to add Peter Crnkovich as a director of BioTheryX. His vast experience in the biopharma capital markets and as a strategic advisor to companies in the biopharma industry will be of tremendous value as BioTheryX enters the clinic with its lead multi-kinase inhibitor, and drives forward its first-in-class "molecular glue" Protein Homeostatic Modulators ("PHMs") and bifunctional protein degraders.'